{"schema_version":"secwatch.filing_event.v1","accession":"0001096906-22-000245","form_type":"8-K","ticker":"UTMD","cik":"0000706698","company_name":"UTAH MEDICAL PRODUCTS INC","filed_at":"2022-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:09.485138+00:00","generated_at":"2026-06-27T12:36:32.398653+00:00","sec_items":["2.02","9.01","99.1"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"UTMD Q4 EPS $1.127; FY2021 sales $49.1M, net income up 37% YoY","bullets":["Diluted EPS Q4 $1.127 (up 20.6% YoY); FY GAAP EPS $4.041, non-GAAP $4.147.","Full year revenue $49.1M (+16%); gross margin expanded to 63.0% from 60.6%.","Operating income margin 38.5% vs 32.5%; adjusted EBITDA $26.5M (54.1% of sales).","Paid $2.00/share special dividend in Dec 2021 ($7.3M) plus regular $0.285; cash $60.9M.","Management projects 2022 adjusted EBITDA ~$30M, up from prior estimate of $28M."],"urls":{"canonical":"https://secwatch.observer/filing/0001096906-22-000245","json":"https://secwatch.observer/filing/0001096906-22-000245.json","markdown":"https://secwatch.observer/filing/0001096906-22-000245.md","text":"https://secwatch.observer/filing/0001096906-22-000245.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/706698/000109690622000245/0001096906-22-000245-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/706698/000109690622000245/utmd-20220201.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T12:36:32.398653+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}